Reporters.io
Michael Gibney
Pharma Voice
Profile
Contacts
Recent Articles on Subject
1
Michael Gibney
Pharma Voice
Teacher of English. Teacher of politics.
Santiago, Chile
education
politics
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
- 7 days ago
With patent losses on the horizon, Amgen refocuses its business strategy
- 29 days ago
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
- about 1 month ago
AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
- about 1 month ago
Cancer vaccines have stumbled, but the approach is gaining new steam
- about 1 month ago
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
- about 2 months ago
Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma
- about 2 months ago
Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions
- about 2 months ago
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
- about 2 months ago
Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid
- about 2 months ago
Drugmakers prep for bird flu outbreak, despite continued low risk
- about 2 months ago
By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years
- 3 months ago
Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?
- 3 months ago
Subcutaneous options offer convenience for patients — and a valuable window for drugmakers
- 3 months ago
4 closely watched FDA approval dates in 2025 from J&J, Novo and more
- 3 months ago
How pharma was instrumental in President Jimmy Carter’s global health efforts
- 3 months ago
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
- 4 months ago
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
- 4 months ago
GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
- 4 months ago
How Astellas juggles the moving parts of cancer precision medicine development
- 4 months ago
How Alexion markets a rare disease drug by ‘starting with the end in mind’
- 4 months ago
Specialized CROs aim to boost participation among women and other underrepresented groups
- 4 months ago
How the incoming administration could impact FTC’s approach to pharma M&A
- 4 months ago
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
- 4 months ago
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
- 4 months ago
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
- 5 months ago
Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug
- 5 months ago
Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
- 5 months ago
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
- 5 months ago
Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech
- 5 months ago
2024 PharmaVoice 100s: Cancer Care Visionaries
- 5 months ago
Big Pharma earnings hang hope on the next generation of blockbusters
- 5 months ago
2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
- 5 months ago
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
- 5 months ago
Why pharma megamergers may become a relic of the past
- 5 months ago
2024 PharmaVoice 100s: Biotech Pathfinders
- 5 months ago
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
- 5 months ago
As new Alzheimer’s biomarkers come into play, here’s where the money is going
- 6 months ago
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
- 6 months ago
Will a Medicare boost propel digital therapeutics to the mainstream?
- 6 months ago
Flu vaccination rates are falling despite record child deaths. Can innovation save the day?
- 6 months ago
Top pharma and biotech conferences 2025
- 6 months ago
How Lilly’s sustainability goals come face to face with massive growth
- 7 months ago
A new way of determining a drug’s value — with health equity in mind
- 7 months ago
Huntington’s disease R&D is regaining ground after several disappointments
- 7 months ago
Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that.
- 7 months ago
A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market
- 7 months ago
Their Alzheimer’s treatment worked — but shares fell anyway
- 7 months ago
Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.
- 7 months ago
23andMe inches closes to cancer immunotherapy, guided by its genetic database
- 8 months ago